Biomarker profiling for risk of future heart failure (HFpEF) development

Chris J Watson, Joe Gallagher, Mark Wilkinson, Adam Russell-Hallinan, Isaac Tea, Stephanie James, James O'Reilly, Eoin O'Connell, Shuaiwei Zhou, Mark Ledwidge, Ken McDonald

Research output: Contribution to journalArticlepeer-review

88 Downloads (Pure)


BACKGROUND: The purpose of this study was to investigate the utility of BNP, hsTroponin-I, interleukin-6, sST2, and galectin-3 in predicting the future development of new onset heart failure with preserved ejection fraction (HFpEF) in asymptomatic patients at-risk for HF.

METHODS: This is a retrospective analysis of the longitudinal STOP-HF study of thirty patients who developed HFpEF matched to a cohort that did not develop HFpEF (n = 60) over a similar time period. Biomarker candidates were quantified at two time points prior to initial HFpEF diagnosis.

RESULTS: HsTroponin-I and BNP at baseline and follow-up were statistically significant predictors of future new onset HFpEF, as was galectin-3 at follow-up and concentration change over time. Interleukin-6 and sST2 were not predictive of future development of new onset HFpEF in this study. Unadjusted biomarker combinations of hsTroponin-I, BNP, and galectin-3 could significantly predict future HFpEF using both baseline (AUC 0.82 [0.73,0.92]) and follow-up data (AUC 0.86 [0.79,0.94]). A relative-risk matrix was developed to categorize the relative-risk of new onset of HFpEF based on biomarker threshold levels.

CONCLUSION: We provided evidence for the utility of BNP, hsTroponin-I, and Galectin-3 in the prediction of future HFpEF in asymptomatic event-free populations with cardiovascular disease risk factors.

Original languageEnglish
Article number61
Number of pages10
JournalJournal of Translational Medicine
Publication statusPublished - 09 Feb 2021


Dive into the research topics of 'Biomarker profiling for risk of future heart failure (HFpEF) development'. Together they form a unique fingerprint.

Cite this